Overview
A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty. The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.Phase:
Phase 4Details
Lead Sponsor:
University Hospital FreiburgCollaborator:
Hoffmann-La RocheTreatments:
Mycophenolate mofetil
Mycophenolic Acid
Criteria
Inclusion Criteria:- Keratoplasty with increased risk for immunologic graft rejection in the abscence of
other risk factors for graft failure. (repeat keratoplasty, steroid-response,
limbo-keratoplasty, oversized graft.
Exclusion Criteria:
- Normal risk cases. Herpes-Keratitis. Glaucoma. Limbus stem cell deficiency.